By Professor Andrew David Carr

Journal articles

Petoumenos K; Carr AD, 2003, 'The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV Observational database', Journal of Clinical Virology, 26, pp. 209 - 222

Smith DG; Carr AD; Law MG; Martin A; Hoy JF; Hudson J; Cooper DA, 2003, 'Thymidine analogue withdrawal for patients on protease sparing therapy improves lipoatrophy but compromises antivrial control:the PIILR extension study', AIDS, 16, pp. 2489 - 2491, http://journals.lww.com/aidsonline/fulltext/2002/12060/thymidine_analogue_withdrawal_for_lipoatrophic.20.aspx

Carr AD, 2003, 'Toxicity of antiretroviral therapy and implications for drug development', Nature Rev Drug Discov, 2, pp. 624 - 634

Carr A; Cooper DA, 2002, 'Fumagillin for intestinal microsporidiosis', NEW ENGLAND JOURNAL OF MEDICINE, 347, pp. 1381 - 1381, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178781300027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carr A; Cooper DA; Molina JM; Tourneur M, 2002, 'Fumagillin for intestinal microsporidiosis [4] (multiple letters)', New England Journal of Medicine, 347, pp. 1381, http://dx.doi.org/10.1056/NEJM200210243471719

Mikhailof N; Carr A; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy [1] (multiple letters)', Journal of the American Medical Association, 288, pp. 1716, http://dx.doi.org/10.1001/jama.288.14.1716

French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D; investigators* OBOO2, 2002, 'Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study', HIV Research & Clinical Practice, 3, pp. 177 - 185, http://dx.doi.org/10.1310/hct.2002.3.3.001

Carr A; Cooper D; Darbyshire J; Dubé M; Peto T; Raghavan S; Reiss P; Walker S; Weller I; Zackin R, 2002, 'The evaluation of metabolic function and fat redistribution in clinical trials', HIV Medicine, 3, pp. 65 - 72, http://dx.doi.org/10.1046/j.1464-2662.2001.00099.x

Moyle G; Carr A, 2002, 'HIV-associated lipodystropy, metabolic complications, and antiretroviral toxicities', HIV Clinical Trials, 3, pp. 89 - 98

Miller J; Brown DA; Amin J; Kent-Hughes J; Law MG; Cooper DA; Carr AD, 2002, 'A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia', AIDS, 16, pp. 2195 - 2200

Carr AD; Workman C; Smith DE; Hoy JF; Hudson J; Doong N; Martin A; Amin J; Freund J; Law MG; Cooper DA, 2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy', JAMA - Journal of the American Medical Association, 288, pp. 207 - 215

Gan SK; Samaras K; Thompson CH; Kraegen EW; Carr AD; Cooper DA; Chisholm DJ, 2002, 'Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy', Diabetes, 51, pp. 3163 - 3169

Wilkinson J; Zaunders J; Carr AD; Guillemin GJ; Cooper DA, 2002, 'Characterization of the phenotypic and lymphokine profile associated with strong CD8+ anti-HIV-1 suppressor activity (CASA', Clinical and Experimental Immunology, 127, pp. 145 - 150

Vanhems P; Routy J; Hirschel B; Baratin D; Vora S; Carr AD; Maenza J; Trepo C; Touraine JL; Gillibert R; Collier AC; Cooper DA; Vizzard J; Sekaly R; fabry J; Perrin L, 2002, 'Clinical features of the acute retroviral syndrome differ by route of infection but not by gender and age', Journal of Acquir Immun Defic Syndrome, 31, pp. 318 - 321

Carr AD; Workman C; Smith DE; Hoy JF; Doong N; Amin J; Law MG; Cooper DA, 2002, 'For the MITOX investigators: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial', Journal of the American Medical Association, 288, pp. 207 - 215

Carr AD; Cooper DA, 2002, 'Fumagillin for microsporidiosis', New England Journal of Medicine, 347, pp. 1381 - 1381

Carr AD; Cooper DA, 2002, 'Fumagillin treatment of intestinal microsporidiosis', New England Journal of Medicine, 347, pp. 1381

Mallon PW; Carr AD; Cooper DA, 2002, 'HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways', Current Diabetes Reports, 2, pp. 116 - 124

Carr AD, 2002, 'Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy', The Lancet, 360, pp. 81 - 85

Carr AD; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy', Journal of the American Medical Association, 288, pp. 1716

Carr AD, 2002, 'Liver dysfunction associated with antiretroviral therapy', HIVINSITE, pp. 1

Schambelan M; Benson CA; Carr AD; Currier JS; Dube MP; Gerber JG; Grinspoon SK; Grunfeld C; Kotler DP; Mulligan K; Powderly W; Saag MS, 2002, 'Management of the metabolic complications assoicated with antiretroviral therapy for HIV-1 infection:recommedations of an International AIDS society-USA', Journal of Acquir Immun Defic Syndrome, 31, pp. 257 - 275

French MA; Amin J; Roth N; Law MG; Emery S; Drummond F, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185

Baker D; Law MG; Petoumenos K; Smith DE; Anderson JA; Roth N; Mallal SA, 2002, 'Rates of combination antiretroviral treatment change in Australia, 1997-2000', HIV Medicine, 3, pp. 28 - 36

Carr AD; Law MG; Baker D; Petoumenos K; Smith D; Anderson JA; Roth N; Mallal SS, 2002, 'Rates of combination antiretroviral treatment change in Australia', HIV Medicine, 3, pp. 28 - 36

Vanhems P; Caillat-Vallet E; Hirschel B; Routy J; Carr AD; Vizzard J; Cooper DA; Perrin L, 2002, 'The CD4 cell count 3 months after acute retroviral syndrome is associated with the presence of AIDS in the source individual', AIDS, 16, pp. 2234 - 2236

Vandems V; Caillat-Vallet E; Hirschel B; Routy J; Carr AD; Vizzard J; Cooper DA; Perrin L, 2002, 'The CD4 cell count 3 months after severe retroviral syndrome is associated with the presence of AIDS in the source individual', AIDS, 16, pp. 2234 - 2236

Smith DE; Carr AD; Law MG; Hudson J; Hoy JF; Cooper DA, 2002, 'Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study', AIDS, 16, pp. 2489 - 2491

Carr AD, 2002, 'Virologic outcomes of complex drug regimens for human immunodeficiency virus', Journal of the American Medical Association, 288, pp. 2405 - 2406

Powderly WG; Carr A, 2001, 'AIDS 2001. Clinical treatment. Overview.', AIDS, 15 Suppl 5

Powderly WG; Carr A, 2001, 'Clinical treatment', AIDS, 15, http://dx.doi.org/10.1097/00002030-200100005-00019

Mooser V; Carr A, 2001, 'Antiretroviral therapy-associated hyperlipidaemia in HIV disease', Current Opinion in Lipidology, 12, pp. 313 - 319, http://dx.doi.org/10.1097/00041433-200106000-00011

Carr A; Morey A; Mallon P; Williams D; Thorburn DR, 2001, 'Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia', Lancet, 357, pp. 1412 - 1414, http://dx.doi.org/10.1016/S0140-6736(00)04579-7

Blanco F; Carr A, 2001, 'Lipodystrophy syndrome: Diagnostic, clinic and therapeutic aspects', AIDS Reviews, 3, pp. 98 - 105

Carr A, 2001, 'Osteopenia in HIV infection.', AIDS clinical care, 13

Gan SK; Samaras K; Carr AD; Chisholm DJ, 2001, 'Anti-retroviral therapy, insulin resistance and lipodystrophy', Diabetes Obesity and Metabolism, pp. 67 - 71

Carr AD; Hudson J; Chuah J; Law MG; Mallal SA; Hoy JF; Doong N; French MA; Smith DE; Cooper DA, 2001, 'HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study', AIDS, 15, pp. 1811 - 1822

Mallon PW; Cooper DA; Carr AD, 2001, 'HIV¿associated lipodystrophy.', HIV Medicine, 2, pp. 166 - 173

Zaunders J; Kaufmann GR; Cunningham PH; Smith DE; Grey PA; Suzuki K; Carr AD; Goh L; Cooper DA, 2001, 'Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.', Journal of Infectious Diseases, 183, pp. 736 - 743

Carr AD; Miller J; Eisman JA; Cooper DA, 2001, 'Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy', AIDS, 15, pp. 703 - 709

Sabin CA; Olmscheid B; Moyle G; Carr A; Boyle B; Cohen C; Cooper D; Deeks S; Gulick T; Saag M, 2001, 'Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois.', HIV Clin Trials, 2, pp. 366 - 386, http://dx.doi.org/10.1310/FPDY-DK6J-GLTV-HC50

Carr AD; Baker D; Petoumenos K; Law MG; Smith D; Roth N; Anderson JA; Mallal SS, 2001, 'Time trends in antiretroviral treatment use in Australia', Venereology - the Interdisciplinary International Journal of Sexual Health, 14, pp. 162 - 168

Carr A; Yarchoan R, 2000, 'AIDS 2000. Clinical treatment: overview.', AIDS, 14 Suppl 3

Carr A, 2000, 'HIV protease inhibitor-related lipodystrophy syndrome', Clinical Infectious Diseases, 30, http://dx.doi.org/10.1086/313854

Carr A; Morey A; Cooper DA; Thorburn DR, 2000, 'Chronic liver failure and persistent mitochondrial dysfunction 2 years after nucleoside reverse transcriptase inhibitor (NRTI)-induced acute hepatitis and lactic acidemia', AIDS, 14, pp. S64 - S64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165192300211&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carr A, 2000, 'Lipodystrophy syndrome: Developing a case definition', AIDS, 14, pp. S13 - S13, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165192300040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sobanski MA; Barnes RA; Gray SJ; Carr AD; Kaczmarski EB; O'Rourke A; Murphy K; Cafferkey M; Ellis RW; Pidcock K; Hawtin P; Coakley WT, 2000, 'Measurement of serum antigen concentration by ultrasound-enhanced immunoassay and correlation with clinical outcome in meningococcal disease', EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 19, pp. 260 - 266, http://dx.doi.org/10.1007/s100960050473

Carr AD; Chuah J; Hudson J; French MA; Hoy JF; Law MG; Sayer D; Emery S; Cooper DA; On BOTC, 2000, 'A randomised, open-label comparison of three highly active antiretroviral therapy regimes including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study', AIDS, 14, pp. 1171 - 1180

Carr AD; Mills J; Law MG; Cooper DA, 2000, 'A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome', AIDS, 14, pp. 25 - 32

Carr AD; Cooper DA, 2000, 'Adverse effects of antiretroviral therapy', Lancet, pp. 1423 - 1430

Back to profile page